Search Antibody Database

Found 1 matching record:

Displaying record number 863

Download this epitope record as JSON.

MAb ID	126-50
HXB2 Location	Env	Env Epitope Map
Author Location	gp41( HXB2)
Epitope	(Discontinuous epitope)
Subtype	B
Ab Type	gp41 cluster II
Neutralizing
Species (Isotype)	human(IgG2κ)
Patient
Immunogen	HIV-1 infection
Keywords	ADCC, review

Notes

Showing 5 of 5 notes.

126-50: The complexity of the epitopes recognized by ADCC responses in HIV-1 infected individuals and candidate vaccine recipients is discussed in this review. 126-50 is discussed as the Cluster II (HR2)region-targeting, non-neutralizing anti-gp41 mAb exhibiting ADCC activity and having a discontinuous epitope. Pollara2013 (ADCC, review)
126-50: Specific for a conformational epitope. Xu1991
126-50: No enhancing or neutralizing activity. Robinson1991
126-50: Directed antibody-dependent cellular cytotoxicity, ADCC. Tyler1990 (ADCC)
126-50: No enhancing activity for HIV-1 IIIB. Robinson1990a

References

Showing 5 of 5 references.

Pollara2013 Justin Pollara, Mattia Bonsignori, M. Anthony Moody, Marzena Pazgier, Barton F. Haynes, and Guido Ferrari. Epitope Specificity of Human Immunodeficiency Virus-1 Antibody Dependent Cellular Cytotoxicity (ADCC) Responses. Curr. HIV Res., 11(5):378-387, Jul 2013. PubMed ID: 24191939. Show all entries for this paper.

Robinson1990a W. E. Robinson, Jr., T. Kawamura, M. K. Gorny, D. Lake, J.-Y. Xu, Y. Matsumoto, T. Sugano, Y. Masuho, W. M. Mitchell, E. Hersh, and S. Zolla-Pazner. Human Monoclonal Antibodies to the Human Immunodeficiency Virus Type 1 (HIV-1) Transmembrane Glycoprotein gp41 Enhance HIV-1 Infection In Vitro. Proc. Natl. Acad. Sci. U.S.A., 87:3185-3189, 1990. Three gp41 MAbs out of 16 Env and Gag MAbs tested enhanced HIV-1 IIIB infection of MT-2 cells. The enhancing antibodies were competitive with the immunodominant epitopes of gp41 recognized by sera from HIV-1 infected subjects. PubMed ID: 2326277. Show all entries for this paper.

Robinson1991 W. E. Robinson, M. K. Gorny, J.-Y. Xu, W. M. Mitchell, and S. Zolla-Pazner. Two Immunodominant Domains of gp41 Bind Antibodies Which Enhance Human Immunodeficiency Virus Type 1 Infection In Vitro. J. Virol., 65:4169-4176, 1991. PubMed ID: 2072448. Show all entries for this paper.

Tyler1990 D. S. Tyler, S. D. Stanley, S. Zolla-Pazner, M. K. Gorny, P. P. Shadduck, A. J. Langlois, T. J. Matthews, D. P. Bolognesi, T. J. Palker, and K. J. Weinhold. Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J. Immunol., 145:3276-3282, 1990. PubMed ID: 1700004. Show all entries for this paper.

Xu1991 J.-Y. Xu, M. K. Gorny, T. Palker, S. Karwowska, and S. Zolla-Pazner. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J. Virol., 65:4832-4838, 1991. The immunodominance of linear epitope in the region 590-600 of gp41 (cluster I) was established, and a second conformational epitope was mapped that reacted with a region between amino acids 644 and 663 (cluster II). Titration experiments showed that there was 100-fold more antibody to cluster I than cluster II in patient sera. PubMed ID: 1714520. Show all entries for this paper.